JN Medsys is a commercial biotechnology company established at the end of 2010. Since its establishment, the company's goal has been to develop simplified basic medical diagnostic tools that enable more people to use them, starting from the digital PCR market. The company was founded by Dr. Huang Jianguo, who has over ten years of experience in developing innovative DNA diagnostic platform technologies. Dr. Huang graduated from the National University of Singapore with a bachelor's and doctoral degree, and currently serves as the CEO of Jahn Biotech. The company received TECS Proof of Concept (POC) funding from the Singapore government in 2011 and subsequently received Proof of Value (POV) funding in 2013. The company has successfully gone through several rounds of financing, with Seeds Capital jointly investing in early 2016 and most recently at the end of 2019. With strong support from the Singapore Enterprise Development Authority, the company has established a core team and capabilities, and completed the development of the first and second generations of Clarity Digital PCR (dPCR) system.

The company launched the Clarity dPCR system at the end of 2015. The Clarity dPCR system is based on the company's proprietary chip tube technology, which can quickly and effectively divide PCR samples into 10000 discrete partitions. Therefore, each partition contains 1 or 0 copies of target DNA or RNA, providing a highly sensitive and accurate method for absolute quantification of nucleic acids of interest. The Clarity system stands out among competitors due to its one of the fastest and simplest digital PCR workflows. Due to its high throughput and affordability, it is also suitable for routine clinical diagnostic purposes.

In 2020, the company launched the second-generation digital PCR system called Clarity Plus. This system has made significant improvements compared to Clarity, with 45000 partitions per reaction and equipped with the world's first 6-color digital PCR system. The more partitions there are, the higher the sensitivity and accuracy, while increasing the number of detection channels by three times can detect more targets in each reaction. Clarity Plus provides a high-precision, high-throughput, and highly reusable system that allows for absolute quantification of nucleic acids using digital PCR. The development of Clarity Plus was also supported by the Singapore Enterprise Development Authority's 2017 Capacity Development Grant.